Embolx's Next-Generation Sniper Balloon Occlusion Microcatheters Approved in Europe
September 5, 2018—Embolx, Inc., which develops microcatheters for arterial embolization procedures, announced CE Mark certifications for its next-generation Sniper balloon occlusion microcatheters designed to deliver pressure-directed arterial embolization therapy to treat cancerous tumors, enlarged prostate, and uterine fibroids. The company's system of microcatheters is now commercially available in the United States and Europe. The company announced FDA approval in June.
According to Embolx, Sniper microcatheters increase therapeutic agent delivery to target areas by controlling pressure and altering blood flow, while protecting surrounding healthy tissues. The next-generation Sniper microcatheters are available in lengths of 110, 130, and 150 cm, which enables access through femoral or radial arterial sites. The company noted that advancements in the Sniper balloon and atraumatic tip designs allow occlusion of larger vessels and enhance the ability for Sniper to track inside vessels.
The company further stated that with its ability to eliminate reflux and redirect blood flow away from surrounding organs, the Sniper is an effective device for prostate artery embolization (PAE) procedures. The United Kingdom’s National Institute for Health and Care Excellence recently issued support of PAE for the treatment of patients with benign prostatic hyperplasia.
In the Embolx announcement, Tiago Bilhim, MD, an interventional radiologist at Hospital Saint Louis in Lisbon, Portugal, commented, “We’ve used Sniper in approximately 50 PAE [procedures] so far this year, and we’ve seen improved outcomes with fewer adverse events when compared to conventional microcatheter embolization. Because Sniper prevents reflux and redirects blood and embolic flow, coils are not needed in these procedures. In addition, the new 150-cm length allows us to perform PAE using a transradial approach.”